GB201415347D0 - Signalling system - Google Patents

Signalling system

Info

Publication number
GB201415347D0
GB201415347D0 GBGB1415347.2A GB201415347A GB201415347D0 GB 201415347 D0 GB201415347 D0 GB 201415347D0 GB 201415347 A GB201415347 A GB 201415347A GB 201415347 D0 GB201415347 D0 GB 201415347D0
Authority
GB
United Kingdom
Prior art keywords
signalling system
signalling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1415347.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1415347.2A priority Critical patent/GB201415347D0/en
Publication of GB201415347D0 publication Critical patent/GB201415347D0/en
Priority to KR1020177007191A priority patent/KR102222615B1/ko
Priority to EP15757558.0A priority patent/EP3185875B1/en
Priority to PCT/GB2015/052494 priority patent/WO2016030691A1/en
Priority to NZ728674A priority patent/NZ728674A/en
Priority to AU2015308243A priority patent/AU2015308243B2/en
Priority to RU2017105515A priority patent/RU2731638C2/ru
Priority to ES15757558T priority patent/ES2910008T3/es
Priority to SG11201700171VA priority patent/SG11201700171VA/en
Priority to BR112017003906-0A priority patent/BR112017003906A2/pt
Priority to EP21193028.4A priority patent/EP3981417A1/en
Priority to MX2017000616A priority patent/MX376613B/es
Priority to CN201580045056.1A priority patent/CN106573989B/zh
Priority to JP2017511182A priority patent/JP6614619B2/ja
Priority to CA2955668A priority patent/CA2955668A1/en
Priority to US15/506,383 priority patent/US10654927B2/en
Priority to IL250101A priority patent/IL250101B/en
Priority to ZA2017/00466A priority patent/ZA201700466B/en
Priority to CL2017000438A priority patent/CL2017000438A1/es
Priority to US16/848,717 priority patent/US20210032332A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1415347.2A 2014-08-29 2014-08-29 Signalling system Ceased GB201415347D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1415347.2A GB201415347D0 (en) 2014-08-29 2014-08-29 Signalling system
US15/506,383 US10654927B2 (en) 2014-08-29 2015-08-28 Signalling system
SG11201700171VA SG11201700171VA (en) 2014-08-29 2015-08-28 Signalling system
EP21193028.4A EP3981417A1 (en) 2014-08-29 2015-08-28 Signalling system
PCT/GB2015/052494 WO2016030691A1 (en) 2014-08-29 2015-08-28 Signalling system
NZ728674A NZ728674A (en) 2014-08-29 2015-08-28 Signalling system
AU2015308243A AU2015308243B2 (en) 2014-08-29 2015-08-28 Signalling system
RU2017105515A RU2731638C2 (ru) 2014-08-29 2015-08-28 Сигнальная система
ES15757558T ES2910008T3 (es) 2014-08-29 2015-08-28 Sistema de señalización
KR1020177007191A KR102222615B1 (ko) 2014-08-29 2015-08-28 신호전달 시스템
BR112017003906-0A BR112017003906A2 (pt) 2014-08-29 2015-08-28 sistema de sinalização
EP15757558.0A EP3185875B1 (en) 2014-08-29 2015-08-28 Signalling system
MX2017000616A MX376613B (es) 2014-08-29 2015-08-28 Sistema de señalización de receptor antigenico quimerico (car).
CN201580045056.1A CN106573989B (zh) 2014-08-29 2015-08-28 信号传导系统
JP2017511182A JP6614619B2 (ja) 2014-08-29 2015-08-28 シグナル伝達系
CA2955668A CA2955668A1 (en) 2014-08-29 2015-08-28 Chimeric antigen receptor (car) signalling system
IL250101A IL250101B (en) 2014-08-29 2017-01-15 Signalling system
ZA2017/00466A ZA201700466B (en) 2014-08-29 2017-01-19 Signalling system
CL2017000438A CL2017000438A1 (es) 2014-08-29 2017-02-23 Sistema de señalización
US16/848,717 US20210032332A1 (en) 2014-08-29 2020-04-14 Signalling system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1415347.2A GB201415347D0 (en) 2014-08-29 2014-08-29 Signalling system

Publications (1)

Publication Number Publication Date
GB201415347D0 true GB201415347D0 (en) 2014-10-15

Family

ID=51752358

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1415347.2A Ceased GB201415347D0 (en) 2014-08-29 2014-08-29 Signalling system

Country Status (18)

Country Link
US (2) US10654927B2 (https=)
EP (2) EP3185875B1 (https=)
JP (1) JP6614619B2 (https=)
KR (1) KR102222615B1 (https=)
CN (1) CN106573989B (https=)
AU (1) AU2015308243B2 (https=)
BR (1) BR112017003906A2 (https=)
CA (1) CA2955668A1 (https=)
CL (1) CL2017000438A1 (https=)
ES (1) ES2910008T3 (https=)
GB (1) GB201415347D0 (https=)
IL (1) IL250101B (https=)
MX (1) MX376613B (https=)
NZ (1) NZ728674A (https=)
RU (1) RU2731638C2 (https=)
SG (1) SG11201700171VA (https=)
WO (1) WO2016030691A1 (https=)
ZA (1) ZA201700466B (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
EP3288570A4 (en) * 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
GB201602571D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602563D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
CA3030003A1 (en) * 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018067993A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP2019535262A (ja) 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
JP7132249B2 (ja) * 2017-05-15 2022-09-06 オートラス リミテッド キメラ抗原受容体（ｃａｒ）を含む細胞
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201709508D0 (en) * 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
CN107475276A (zh) * 2017-09-05 2017-12-15 深圳大学 嵌合抗原受体及其表达基因、四环素调节的嵌合抗原受体修饰的t细胞及其应用
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
GB201805918D0 (en) * 2018-04-10 2018-05-23 Autolus Ltd Cell
EP3774866A1 (en) 2018-04-13 2021-02-17 Ludwig Institute for Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
GB201807693D0 (en) 2018-05-11 2018-06-27 Autolus Ltd Cell
WO2019220109A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
AU2019335014A1 (en) * 2018-09-05 2021-03-25 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
IL281428B2 (en) 2018-09-27 2024-10-01 Autolus Ltd Chimeric antigen receptor
GB201816839D0 (en) * 2018-10-16 2018-11-28 Glaxosmithkline Ip Dev Ltd Novel control switch
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201906202D0 (en) 2019-05-02 2019-06-19 Autolus Ltd Cell
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
WO2021009510A1 (en) 2019-07-16 2021-01-21 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201913258D0 (en) 2019-09-13 2019-10-30 Autolus Ltd Antigen-binding domain
GB201919019D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
US20230133554A1 (en) 2020-04-09 2023-05-04 Autolus Limited Molecule
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
GB202017343D0 (en) 2020-11-02 2020-12-16 Autolus Ltd Cell
GB202104030D0 (en) 2021-03-23 2021-05-05 Autolus Ltd Signalling system
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
GB202219568D0 (en) 2022-12-22 2023-02-08 Autolus Ltd Chimeric antigen receptor
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789446A1 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
FI2997141T3 (fi) 2013-05-13 2022-12-15 CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
MX373687B (es) * 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
US9791929B2 (en) * 2014-10-31 2017-10-17 Elwha Llc Tactile control system
PL3560953T3 (pl) * 2014-12-24 2024-05-13 Autolus Limited Komórka
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
IL260532B2 (en) * 2016-01-11 2023-12-01 Univ Leland Stanford Junior Chimeric proteins- containing systems and uses thereof in regulating gene expression
GB201602563D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602571D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201610515D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Cell

Also Published As

Publication number Publication date
ES2910008T3 (es) 2022-05-11
EP3185875A1 (en) 2017-07-05
IL250101A0 (en) 2017-03-30
RU2731638C2 (ru) 2020-09-07
RU2017105515A (ru) 2018-10-01
NZ728674A (en) 2020-05-29
JP6614619B2 (ja) 2019-12-04
SG11201700171VA (en) 2017-02-27
WO2016030691A1 (en) 2016-03-03
MX2017000616A (es) 2017-07-20
US20170260269A1 (en) 2017-09-14
BR112017003906A2 (pt) 2018-02-27
EP3185875B1 (en) 2022-01-05
MX376613B (es) 2025-03-07
US10654927B2 (en) 2020-05-19
KR20170045258A (ko) 2017-04-26
RU2017105515A3 (https=) 2018-10-01
IL250101B (en) 2020-11-30
JP2017526361A (ja) 2017-09-14
CN106573989B (zh) 2022-02-01
CA2955668A1 (en) 2016-03-03
AU2015308243A1 (en) 2017-02-23
EP3981417A1 (en) 2022-04-13
CL2017000438A1 (es) 2017-08-18
CN106573989A (zh) 2017-04-19
AU2015308243B2 (en) 2020-01-30
KR102222615B1 (ko) 2021-03-05
US20210032332A1 (en) 2021-02-04
ZA201700466B (en) 2018-08-29

Similar Documents

Publication Publication Date Title
ZA201700466B (en) Signalling system
IL251719A0 (en) Cyber security system
GB201405845D0 (en) Signalling system
GB201501936D0 (en) Signalling system
PL3855782T3 (pl) Układ sygnalizacji dla systemu bezprzewodowego
GB201417453D0 (en) Location system
GB201421498D0 (en) Ventalation System
GB201602563D0 (en) Signalling system
GB201403908D0 (en) Communicatioon system
GB201602571D0 (en) Signalling system
EP3254897C0 (en) SIGNALING SYSTEM
GB2538450B (en) Signal system
GB201411097D0 (en) 329 - octo-lateral system
GB201413985D0 (en) Improved ACAES system
GB201405654D0 (en) Mounting system
PL3087213T3 (pl) Instalacja przelotowa
SG10201500603SA (en) Monitoring-And-Control System
GB2530120B (en) Alarm system
GB201620472D0 (en) Signalling device
GB201602569D0 (en) Signalling system
GB201417116D0 (en) Telescopic-lateral system
GB201417063D0 (en) System
GB201413642D0 (en) System
GB201411684D0 (en) Detecttion system
GB201411329D0 (en) Octopus-lateral system

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)